Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.
Biogen and Bio-Thera Solutions have entered into a commercialisation and license agreement for the development, manufacturing and commercialisation of BAT1806.
Piramal Pharma (PPL), a subsidiary of Piramal Enterprises, has agreed to acquire 100% stake in Indian peptide APIs manufacturer Hemmo Pharmaceuticals, for $105.6m (INR7.75bn).
Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases.
The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK).
Moderna has announced plans to increase its global manufacturing capacity for Covid-19 vaccine by making additional capital investments.
Cambridge-based global, science-led biopharmaceutical company AstraZeneca and German manufacturer of viral vaccines and biologics IDT Biologika have signed a Letter of Intent (LOI) to increase Europe’s Covid-19 vaccine manufacturing capability.
Ocugen, a Pennsylvania-based pharmaceutical company, has signed an agreement with Bharat Biotech, an Indian pharma developer of COVAXIN, a Covid-19 vaccine, to distribute the vaccine in the US.
WuXi STA, a subsidiary of Chinese pharmaceutical company WuXi AppTec, has agreed to buy the Couvet, Switzerland-based manufacturing facility from Bristol Myers Squibb.
Humanigen has announced an expansion to the Cooperative Research and Development Agreement (CRADA) with the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.